Atossa Genetics (NASDAQ:ATOS – Get Free Report) and QHSLab (OTCMKTS:USAQ – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Atossa Genetics and QHSLab”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atossa Genetics | N/A | N/A | -$34.77 million | ($3.21) | -0.75 |
| QHSLab | $2.69 million | 0.99 | $460,000.00 | $0.03 | 7.90 |
Profitability
This table compares Atossa Genetics and QHSLab’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atossa Genetics | N/A | -84.91% | -72.36% |
| QHSLab | 15.60% | -27.74% | -6.98% |
Insider & Institutional Ownership
12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 74.2% of QHSLab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Atossa Genetics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, QHSLab has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Atossa Genetics and QHSLab, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atossa Genetics | 2 | 0 | 3 | 0 | 2.20 |
| QHSLab | 0 | 0 | 0 | 0 | 0.00 |
Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 747.22%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Atossa Genetics is more favorable than QHSLab.
Summary
QHSLab beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.
About Atossa Genetics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
About QHSLab
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
